Prometheus Biosciences News

Slightly above 67% of Prometheus Biosciences' investor base is looking to short. The analysis of current outlook of investing in Prometheus Biosciences suggests that many traders are alarmed regarding Prometheus Biosciences' prospects. Prometheus Biosciences' investing sentiment can be driven by a variety of factors including economic data, Prometheus Biosciences' earnings reports, geopolitical events, and overall market trends.
  
over a week ago at benzinga.com         
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset JP Morgan Analyst
benzinga news
over a month ago at thelincolnianonline.com         
Acquisition by Baumal Caroline of 594 shares of Apellis Pharmaceuticals subject to Rule 16b-3
news
over two weeks ago at finance.yahoo.com         
What To Expect From Apellis Pharmaceuticals Inc Q4 2024 Earnings
Yahoo News
over a week ago at thelincolnianonline.com         
Disposition of 14986 shares by Timothy Rolph of Akero Therapeutics at 19.87 subject to Rule 16b-3
news
over two weeks ago at seekingalpha.com         
Akero Therapeutics GAAP EPS of -0.99 beats by 0.17
seekingalpha News
over a month ago at gurufocus.com         
Akero Therapeutics Inc Announces 300 Million Public Offering
Gurufocus Stories at Macroaxis
over a month ago at gurufocus.com         
Deep Track Capital, LP Acquires Significant Stake in Tectonic Therapeutic Inc
Gurufocus Stories at Macroaxis
over a week ago at news.google.com         
Jefferies sets Immunovant stock hold rating, 20 price target - Investing.com
Google News at Macroaxis
over three weeks ago at finance.yahoo.com         
Disposition of 154 shares by Salzmann Peter of Immunovant at 20.86 subject to Rule 16b-3
Yahoo News
few days ago at thelincolnianonline.com         
Disposition of 7742 shares by Craves Fred B of Madrigal Pharmaceuticals at 65.06 subject to Rule 16b...
news
3 days ago at www.macroaxis.com         
Disposition of 1728 shares by Craves Fred B of Madrigal Pharmaceuticals at 65.06 subject to Rule 16b...
Macroaxis News
over two weeks ago at globenewswire.com         
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces N...
Macroaxis News: globenewswire.com
over a week ago at thelincolnianonline.com         
Roivant Sciences Raised to Strong-Buy at Cantor Fitzgerald
news
over two weeks ago at globenewswire.com         
Early Warning Report Issued Pursuant to National Instrument 62103 Roivant announces Resignation and ...
Macroaxis News: globenewswire.com
over a month ago at zacks.com         
All You Need to Know About Montes Archimedes Acquisition Rating Upgrade to Buy
zacks News
over a month ago at finance.yahoo.com         
Roivant Sciences Ltd Q3 2024 Earnings Call Highlights Strategic Moves and Financial ...
Yahoo News
over two weeks ago at globenewswire.com         
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK for the Treatment of Dystrophic Epidermol...
Macroaxis News: globenewswire.com
over three weeks ago at gurufocus.com         
Q4 2024 Krystal Biotech Inc Earnings Call Transcript
Gurufocus Stories at Macroaxis
over a week ago at thelincolnianonline.com         
Jefferies Financial Group Initiates Coverage on Krystal Biotech
news
over three weeks ago at zacks.com         
Should You Buy 89BIO After Golden Cross?
zacks News
over a month ago at gurufocus.com         
Suvretta Capital Management, LLCs Strategic Acquisition in 89bio Inc
Gurufocus Stories at Macroaxis
over a week ago at globenewswire.com         
INVESTOR ALERT Faruqi Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
Macroaxis News: globenewswire.com
over a week ago at benzinga.com         
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future
benzinga news
over two weeks ago at www.macroaxis.com         
Acquisition by Lefebvre Eric of 45650 shares of Pliant Therapeutics subject to Rule 16b-3
Macroaxis News
over a month ago at gurufocus.com         
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b3
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Were Not Worried About Arcellxs Cash Burn
Yahoo News
over two weeks ago at seekingalpha.com         
Arcellx GAAP EPS of -2.00 misses by 0.40, revenue of 107.94M
seekingalpha News
over two weeks ago at www.macroaxis.com         
Disposition of 1500 shares by Patel Kavita of Arcellx at 63.16 subject to Rule 16b-3
Macroaxis News
over a month ago at gurufocus.com         
Paradigm Biocapital Advisors LP Increases Stake in Cogent Biosciences Inc
Gurufocus Stories at Macroaxis
over three weeks ago at globenewswire.com         
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for...
Macroaxis News: globenewswire.com
over a month ago at gurufocus.com         
Lynx1 Capital Management LP Acquires Significant Stake in Precision BioSciences Inc
Gurufocus Stories at Macroaxis
over a month ago at news.google.com         
Stoke Therapeutics Trading Down 5.6 percent - Whats Next - MarketBeat
Google News at Macroaxis
over two months ago at thelincolnianonline.com         
Analysts Set Stoke Therapeutics, Inc. Price Target at 21.29
news
six days ago at finance.yahoo.com         
Novo Nordisks Ozempic successor disappointed Wall Street again
Yahoo News
over a week ago at thelincolnianonline.com         
Viking Therapeutics Stock Price Up 7.8 percent Still a Buy?
news
over a week ago at investors.com         
AbbVie Enters The Obesity Arena. Why Its Paying Up To 2.23 Billion.
Investors Business Daily at Macroaxis
over two weeks ago at globenewswire.com         
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual H...
Macroaxis News: globenewswire.com
over a month ago at gurufocus.com         
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635
Gurufocus Stories at Macroaxis
over a month ago at simplywall.st         
We Think Terns Pharmaceuticals Can Afford To Drive Business Growth
Simply Wall St News at Macroaxis
over a week ago at kalkinemedia.com         
Disposition of 6489 shares by Namouni Fouad of Blueprint Medicines at 88.8 subject to Rule 16b-3
news
over two weeks ago at finance.yahoo.com         
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI WAO J...
Yahoo News
over a month ago at insidermonkey.com         
Blueprint Medicines Corporation Q4 2024 Earnings Call Transcript
insidermonkey News
over a month ago at gurufocus.com         
Insider Sell Kate Haviland Sells Shares of Blueprint Medicines Corp
Gurufocus Stories at Macroaxis
over a week ago at thelincolnianonline.com         
Amylyx Pharmaceuticals Posts Quarterly Earnings Results, Misses Expectations By 0.06 EPS
news
over a week ago at gurufocus.com         
Amylyx Pharmaceuticals Inc Q4 2024 Everything You Need To Know Ahead Of Earnings
Gurufocus Stories at Macroaxis
over a month ago at www.macroaxis.com         
Disposition of 11855 shares by Justin Klee of Amylyx Pharmaceuticals at 3.4672 subject to Rule 16b-3
Macroaxis News
over a week ago at news.google.com         
JPMorgan Chase Co. Lowers Day One Biopharmaceuticals Price Target to 34.00 - Defense World
Google News at Macroaxis
over two weeks ago at zacks.com         
Insider Trading
zacks News
over two weeks ago at businesswire.com         
DAWN calls on International Criminal Court to Investigate Biden administration for Aiding and Abetti...
businesswire News
over three weeks ago at www.macroaxis.com         
Disposition of 12048 shares by Bender Jeremy of Day One at 11.963 subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Prometheus Biosciences that are available to investors today. That information is available publicly through Prometheus media outlets and privately through word of mouth or via Prometheus internal channels. However, regardless of the origin, that massive amount of Prometheus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Prometheus Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Prometheus Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Prometheus Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Prometheus Biosciences alpha.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Consideration for investing in Prometheus Stock

If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Stocks Directory
Find actively traded stocks across global markets
Equity Valuation
Check real value of public entities based on technical and fundamental data